Alnylam Pharmaceuticals Inc. (ALNY)
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates
Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to earnings of $1.15 per share a year ago.
Seeking Clues to Alnylam (ALNY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alnylam (ALNY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, particularly with Amvuttra for ATTR-CM, which could become a major revenue driver in a growing market. Additionally, vutrisiran for ATTR-CM could capture a significant share of a projected $11.2 billion market.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy?
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?
Here is how Alnylam Pharmaceuticals (ALNY) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU
ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR amyloidosis with cardiomyopathy.
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
Here is how Alnylam Pharmaceuticals (ALNY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.
